
Pharmaceutical R&D Developer

Pharmaceutical R&D Developer

Biopharmaceutical Manufacturer

Pharmaceutical Product R&D Developer

Therapeutic Area Product Development and Manufacturing

Innovative Therapeutic Drug Developer

Pharmaceutical Product R&D Developer

Innovative Drug Developer
On August 6, the Fujian Provincial Healthcare Security Administration released the “List of Top 20 Drugs by Sales Volume under Fujian Province’s Joint Price-Capped Sunshine Procurement Program (June 2019).” Half of the listed drugs were injections, with Roche Shanghai’s Trastuzumab for Injection ranking first in sales. Notably, although many of the top-selling drugs in Fujian Province in June were from foreign pharmaceutical companies such as Roche Shanghai, Pfizer, Sanofi, AstraZeneca, and Bayer, there were also numerous domestic enterprises represented. Pharmaceutical companies including HEC CJ PHARM, Shanghai Hutchison Pharmaceuticals, Southwest Pharmaceutical, Jiangsu Hansoh Pharmaceutical, CSPC-NBP Pharmaceutical, NCPC, and Sichuan Luye Pharmaceutical all had products among the top 20 in sales volume. Details are provided in the list below:

Disclaimer: This article is reposted from Yaozhi.com. The copyright belongs to the original author. The purpose of reposting is to convey more information, which does not represent the views of this platform. If there are any issues regarding the content, copyright, or other matters, please leave a message on our website, and we will delete the content promptly.
